Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10(®) to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies

Background. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decisions using specialized algorithms, especially in gastroenterology. A new chemiluminescent instrument (i-TRACK(10®) from Theradiag) could replace ELISA techniques to calculate the dosage of drugs and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Anne Emmanuelle, Gleizes, Aude, Waeckel, Louis, Roblin, Xavier, Krzysiek, Roman, Hacein-Bey-Abina, Salima, Soriano, Alessandra, Paul, Stephane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455629/
https://www.ncbi.nlm.nih.gov/pubmed/36076966
http://dx.doi.org/10.3390/ijms23179561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455629/
https://www.ncbi.nlm.nih.gov/pubmed/36076966
http://dx.doi.org/10.3390/ijms23179561

Ejemplares similares